Company Overview
Company Type: Private Company
Website: flosonicsmedical.com
Number of Employees: -
Year Founded: 2015
Total Amount Raised (CAD mm)†: 23.14
Total Rounds of Funding**:2
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Flosonics Medical manufactures medical devices that focus on non-invasive hemodynamic monitoring. It develops non-invasive sensors to improve the management of critically ill patients. It offers FloPatch, a wearable ultrasound sensor that provides patient blood flow assessments during clinical interventions by sending data wirelessly to mobile devices using low-energy Bluetooth. Flosonics Medical was formerly known as Ke2 Technologies and changed its name to Flosonics Medical in October 2017. The company was founded in 2015 and is based in Sudbury, Canada with an additional office in Toronto, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Eibl, Joseph 
CEO, Co-Founder & Director
Eibl, Andrew 
Co-Founder & COO
Harish, Sachit 
Director of Finance & Co-Founder
Kenny, Jon-Emile 
Chief Medical Officer & Co-Founder

Key Board Members
Name
Title
Magnin, Paul A.
Chairman of the Board
Eibl, Joseph 
CEO, Co-Founder & Director
Foster, Stuart 
Director
Ifergan, Sam 
Director
Kidle, Dan 
Director
Lamb, Damian 
Director
Marik, Paul 
Member of Scientific Advisory Board
Monnet, Xavier 
Member of Scientific Advisory Board
Teboul, Jean-Louis 
Member of Scientific Advisory Board


Primary Industry Classification
Health Care Equipment


Primary Office Location
56 Walford Road | Sudbury, ON | P3E 2H2 | Canada
Phone: 705 626 6419   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Investment Coverage
Arboretum Ventures LLC
Feb-02-2021
Minority
-
Venture
Dan Kidle
Accel-Rx
Jan-29-2018
Minority
-
Seed
-
Genesys Capital Partners Inc.
Jan-29-2018
Unknown
-
Seed
-
iGan Partners
Jan-29-2018
Unknown
-
Seed
-
MaRs Discovery District, Investment Arm
Jan-29-2018
Minority
-
Seed
-


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Feb-02-2021
Feb-02-2021
Private Placement
Target
Flosonics Medical
iGan Partners,Genesys Capital Partners Inc.,Arboretum Ventures LLC

14.00
Jan-29-2018
Jan-29-2018
Private Placement
Target
Flosonics Medical
iGan Partners,Genesys Capital Partners Inc.,Accel-Rx,MaRs Discovery District, Investment Arm Buyer Funds:MaRS Investment Accelerator Fund, MaRs Discovery District - Virgin Unite Fund

4.05
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-21-2023
Client Announcements
Riverside University Health System to Implement FloPatch by Flosonics Medical, Revolutionizing Precision Fluid Management in Sepsis Care
Mar-22-2023
Company Conference Presentations
Flosonics Medical Presents at LSI USA ’23 Emerging Medtech Summit, Mar-22-2023 11:20 AM
Mar-14-2023
Client Announcements
El Camino Health to Adopt FloPatch Advanced Ultrasound Technology for Sepsis Management
Feb-02-2021
Executive/Board Changes - Other
Flosonics Medical Announces Board Changes
Feb-02-2021
Private Placements
Flosonics Medical announced that it has received $14 million in funding from Arboretum Ventures LLC, iGan Partners, Genesys Capital Partners Inc.


Last 10 Investment Research Documents
No Investment Research returned. This can be caused by entitlement settings or your template settings.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Magnin, Paul A.
Chairman of the Board
705 626 6419
-

Eibl, Joseph 
CEO, Co-Founder & Director
705 626 6419
-

Foster, Stuart 
Director
705 626 6419
-

Ifergan, Sam 
Director
705 626 6419
-

Kidle, Dan 
Director
705 626 6419
-

Lamb, Damian 
Director
705 626 6419
-
damian@genesyscapital.com
Marik, Paul 
Member of Scientific Advisory Board
705 626 6419
-
-
Monnet, Xavier 
Member of Scientific Advisory Board
705 626 6419
-
-
Teboul, Jean-Louis 
Member of Scientific Advisory Board
705 626 6419
-
-
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Eibl, Joseph 
CEO, Co-Founder & Director
705 626 6419
-

Eibl, Andrew 
Co-Founder & COO
705 626 6419
-
-
Harish, Sachit 
Director of Finance & Co-Founder
705 626 6419
-
-
Kenny, Jon-Emile 
Chief Medical Officer & Co-Founder
705 626 6419
-
-
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
